C4 Therapeutics Stock Forecast, Price & News

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for C4 Therapeutics in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" C4 Therapeutics stock.
View analyst ratings for C4 Therapeutics or view top-rated stocks.

Wall Street analysts have given C4 Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but C4 Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

C4 Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 12th 2021.
View our earnings forecast for C4 Therapeutics.

C4 Therapeutics, Inc. (NASDAQ:CCCC) posted its earnings results on Thursday, May, 13th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.63) by $0.14. The business earned $7.43 million during the quarter.
View C4 Therapeutics' earnings history.

6 equities research analysts have issued twelve-month target prices for C4 Therapeutics' stock. Their forecasts range from $34.00 to $63.00. On average, they anticipate C4 Therapeutics' stock price to reach $51.50 in the next year. This suggests a possible upside of 15.0% from the stock's current price.
View analysts' price targets for C4 Therapeutics or view top-rated stocks among Wall Street analysts.

Some companies that are related to C4 Therapeutics include Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Halozyme Therapeutics (HALO), Beam Therapeutics (BEAM), Exelixis (EXEL), Adaptive Biotechnologies (ADPT), Recursion Pharmaceuticals (RXRX), Vir Biotechnology (VIR), Abcam (ABCM), Kodiak Sciences (KOD), SpringWorks Therapeutics (SWTX), Ablynx (ABLYF), Iovance Biotherapeutics (IOVA) and Allogene Therapeutics (ALLO).
View all of CCCC's competitors.

(CCCC) raised $150 million in an initial public offering on Friday, October 2nd 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI, BMO Capital Markets and UBS Investment Bank served as the underwriters for the IPO.

C4 Therapeutics trades on the NASDAQ under the ticker symbol "CCCC."

C4 Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Alliancebernstein L.P. (0.14%) and Eagle Health Investments LP (0.11%). Company insiders that own C4 Therapeutics stock include Adam Crystal, Malcolm Salter, Marc A Cohen and William Mckee.
View institutional ownership trends for C4 Therapeutics.

CCCC stock was purchased by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., and Eagle Health Investments LP. Company insiders that have bought C4 Therapeutics stock in the last two years include Marc A Cohen, and William Mckee.
View insider buying and selling activity for C4 Therapeutics or or view top insider-buying stocks.

Shares of CCCC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CCCC stock can currently be purchased for approximately $44.80.

C4 Therapeutics has a market capitalization of $1.94 billion and generates $33.19 million in revenue each year. The company earns $-66,330,000.00 in net income (profit) each year or ($5.83) on an earnings per share basis.

C4 Therapeutics employs 99 workers across the globe.

The official website for C4 Therapeutics is www.c4therapeutics.com.

The company can be reached via phone at 617 231 0700 or via email at [email protected]